Sale!

What Every Woman Should Know about Cervical Cancer

Revised and Updated

฿8,600 ฿6,880

Add to Wishlist
Add to Wishlist
EAN: N/A SKU: 9789402413816 Category:

Book Details

Weight 9581 g
Dimensions 155 × 235 mm
ISBN

9789402413816

Book Cover

Paperback / softback

Publisher

Springer Netherlands

Pages

527

Publishing Date

2018

About The Author

Markovic, Nenad

This book (an
updated and extended edition) is about mobilizing women and health care policy
makers and providers to unite their efforts in a single strategy for fighting
cervical cancer worldwide. The objective of this strategy would be to reverse
cervical cancer prevalence and mortality rates among all 2.4 billion women at
risk and to achieve this goal within 10-15 years of implementation. Cervical
Cancer Screening (Pap test, VIA, VILI, or HPV) failed to stop cervical cancer
worldwide simply because many countries could not afford developing
infrastructure necessary to carry on the global strategy, and because the
outreach could not accomplish the targeted 51% of the population at risk. In
2015, there is still 600,000 women getting cervical cancer annually and 300,000
of them die. Every minute one woman gets cervical cancer and every 2 minutes
one woman dies from this preventable disease.

In 21st Century
the Information Technology (IT) Revolution has made substantial impact on
medicine enabling remote points-of care, scattered around the world, to be
e-connected with experts in distant medical centers and to obtain quality
diagnosis and proper guidelines for curative therapy of early stages of
cervical cancer. Low frequency of costly interventions needed makes IT-based
screening financially and socially beneficial for mass screening.

This new
Mobile Health technology with the Global Strategy for Fighting Cervical Cancer
is subject to elaboration in our book as the new hope when old efforts have
failed to stop the world “epidemics” of this grave but preventable disease. The
language is adapted for easy reading and understanding by professionals and
lay-persons.

This book is
intended for women at risk for cervical cancer, their health care providers,
health insurance companies, government responsible for making health policy and
healthcare industry because all of them have special role in the new Global
Strategy elaborated in details in this book.

Recent introduction of HPV vaccines has raised hopes for immunization against cervical cancer and for the first time in the history of humanity for eradication of one malignant disease. This new “opportunity” has changed many current views on cervical cancer prevention, control diagnosis and treatment. Many canons and guidelines became subject of review and many revisions are coming. This book is intended to summarize most of these events and to present them to all women in a language understandable by the eneral public.


We expect the book will bring all readers the rationale for optimism and will provide guidance as how to gain knowledge and skills for critical thinking and making an educated decision when it will be necessary in their lives.

Prelims

PROLOGUE

CHAPTER
1The
FEMALE  REPRODUCTIVE SYSTEM  IN  HEALTH
 AND DISEASE

 

 
1.1 Basic Anatomy of the Female Reproductive System

1.1.1The
Ovaries

1.1.2 Fallopian
Tubes

1.1.3 The
Uterus

1.1.4The Vagina

1.1.5The Vulva
and the Perineum

                                                                  

1.2     Basic
Physiology of the Female Reproductive System

1.2.1 Female
Hormones

1.2.2 The
Menstrual Cycle

1.2.3  Pregnancy

1.2.4  Menopause

 

1.3.   An Overview
of the Most Common Women’s Diseases

1.3.1 Menstrual
Disorders

1.3.2 Other
Disorders

1.3.3 Common
Infections in Women

1.3.4 Sexually
Transmitted Diseases

 

1.4     
Tumors of the Female Genital System

                1.4.1   Benign Tumors

1.  4.2.
Malignant Tumors other than Cervical Cancer

 

 

CHAPTER
2  

 

CERVICAL
CANCER

 

2.1
About Cervical Cancer and Pre-carcinomatosis

       2.1.1 Introduction

2.12  Definition

2.13   Interpretation

 

2.2
 Epidemiology of Cervical Cancer

 

2.3
 Prevention and Control of Cervical
Cancer

         2.3.1 Risk Factors and Education to
Reduce Their Influence

         2.3.2 Cancer Control: Cervical
Cancer/Pre-carcinomatosis

                   Screening

          2.3.3 Non-cytological based Cervical
Cancer Screening

   
2.3.4  Management of Women When
the Pap test result Returns

2.3.5Biomarkers
and Cervical Cancer

2.3.6Human
Papilloma Virus and Cervical Cancer

 

2.4  Diagnosis and Treatment of Cervical Cancer

2.4.1 Diagnostic Methods

             2.4.2 Staging System

       2.4.3  
Planning Therapy

       2.4.4  
Cervical Cancer Treatment

 

 2.5  Prognosis of Cervical Cancer and How to improve
it

          

CHAPTER
3    LIVING WITH CERVICAL CANCER

 

3.1   Cooping

3.1.1
How to Cope When the Result is Abnormal Pap Test?

3.1.2 The Diagnosis is Cervical Cancer

3.1.3 Support fro Caregivers and Close Family in
Day-by-Day Coping with the Disease

3.1.4 Support of Extended Family and Friends

3.1.5  Support
Groups

 

3.2   Living with Cancer

      3.2.1 Complementary and Alternative
Medicine

3.2.2
  Holistic View of Health and Wellness

3.2.3
  Which are other dimensions of Health
Described as a Holistic Health Model

3.2.4  
How we can
achieve A Higher Level of Wellness Across all Dimensions of Health?

3.2.5  
Understanding
the Mechanism of Stress

3.2.6  
Stress
Release Strategies

3.2.7  
 An overview on Eating for Optimal Health in
Cancer Prevention and Cancer Prevention and Cervical Cancer

 

3.3      
  Stories from Real People

 

      3.4     
Survey on What Women Think About Pap Test

            3.4.1   Background

3.4.2    Identifying 
the Problem

3.4.3    Addressing the Problem

3.4.4    Study Results and Analysis

3.4.5    Conclusion

 

 

CHAPTER

CERVICAL
CANCER SCREENING   AFTER 2008            

4.1.
CURRENT PRACTICES

4.1.1     Afterward to the 2008 Edition:  What we have predicted

4.1.2     What happened with Pap test

4.1.2.1    
Dethroning  classic Pap test

4.1.2.2    
 Disappointment with the global outreach

4.1.2.3    
Failure
of alternatives to repeat the success of the Pap test in the US

4.1.2.4    
Attempt
to balance the screening cost  with the
benefit obtained

4.1.2.5    
Search
for new ideas to reverse the increasing cancer trends worldwide

4.1.2.6    
Change
of the WHO strategy

 

4.1.3    Pap test now

 

4.1.4    Challenges to standard Pap test – An overview

 

4.1.5   Liquid – based cervical cytology.

 

4.1.6 HPV testing and immunization

 

4.1.7 Management of women after
Pap test

 

 

4.2
GUIDELINES

   

   4.2.1 Overview on Guidelines

 

   4.2.2 Individual Guidelines

         4.2.2.1 ACOG

         4.2.2.2 ASC 2015

         4.2.2.3 ASCCP

         4.2.2.4   USPSTF

         4.2.2.5 WHO

 

 

CHAPTER
  5

GLOBAL
CERVICAL CANCER SCREENING

 

5.1   Worldwide Application of Cervical Cancer
Screening

5.2   Cervical Cancer Statistics-world

5.3    Gross Domestic Product per Capita

5.4     Study Summary

5.4.1     Examples

5.4.1.1            
US
India Symposium on Cervical Cancer

5.4.1.2            
India
Press Release 2015

5.4.1.3            
Cervical
Cancer in China Press Release 2015 

5.4.1.4    Republic of Serbia

5.4.2       Continents- World Summary

 

5.5.             
Preliminary
Data Pilot Study

 

5.6   Examples from Individual countries

 

 

 

   CHAPTER 6

   

   NEW STRATEGY and ITS GLOBAL APPLICATION

 

6.1        Executive Summary

6.2    Global Cervical Cancer Screening

6.2.1     
Introduction

6.2.1.1     Why New
Strategy

6.2.1.2     Which
Strategy to Choose

6.2.1.3     New
Strategy Applied for India

6.2.1.4      Instead of Conclusion

 

6.3   MarkPap® Technology Platform

 

6.4   Social Impact: LMIC and Alleviation of
health disparity

 

6.5.        Economic Impact – Cost Benefit

6.5.1    Global Funding and Application of the New
Strategy

6.5.2    Global Benefit

6.5.3    Socio-economic Advantage

 

6.6    Policy Change (India)

 

 

 

 

CHAPTER 7  NEW TOOLS:  MarkPap
Platform Technology Illustrated

 

7.1       MarkPap®
Platform Technology: MarkPap Illustrated

7.1.1 MarkPap®Test   

7.1.2 MarkPap® Reagent Kit with
Accessories

            7.1.3 MarkPap® Specimen Collection
Kit™

            7.1.4
MarkPap® Telecytopathology                        “““““7.1.5 MarkPap®
Digital (Tele -Pap)

7.1.6    MarkPap®
Mobile

 

7.2       IT
Telehealth Center (ITTHC)

 

7.3       The New
Integrative Complex MEDYKO

       7.3.1   
Concept

7.3.2         
Letter

7.3.3         
Methods
Comparison

 

 

7.4       TEMPLATE
for Telecytopathology

 

7.5       Screen and
Treat with MarkPap

 

7.6       Telecytopathology
Protocol

 

Chapter
8     REFERENCES

 

8.1  Ethics

8.2   Literature
Cited

8.3   Where
to Read More

8.4   Index

8.5  EPILOGUE

  CHAPTER
9  ANNEX

 

9.1
Brochures

 

9.1.1
 MarkPap India, LLC.  Fighting Cervical Cancer.

  
Brochure, 2012

 

9.1.2
 MarkPap Pacific, LLC. Cervical Cancer in
China. Brochure. How we can help. 2013

 

9.2   Power Point Presentations

 

9.2.1
 National Institute for Standards and
Technology (NIST).

Lecture
on MarkPap Technology, 2014

9.2.2
 Global Health Challenges: Is worldwide
cytological cervical screening possible? 2105

 

9.2.3MarkPap
Pacific presents: MarkPap® Technology, 2013

 

9.2.4   China Deal Overview. MarkPap Pacific, LLC, 2009

 

<9.2.5. MarkPap Pacific, LLC.
Opportunity in China, 2008

 

9.2.6MarkPap
India, LLC. Cervical Cancer. How we can help. 2012

 

9.2.7  BioSciCon, Inc. Special strategies for
fighting cervical cancer in India. 2015

 

9.2.8   BioSciCon, Inc. Fighting cervical cancer in
Azerbaijan,

2013

 

9.2.9  BioSciCon, Inc. MarkPap technology for prevention
cervical cancer in Africa, 2015

 

9.2.10  Global Academy for Women’s Health. Cervical
Cancer:             Past, present and future.
Invited lecture, 2013. Northern Virginia Community College, NOVA,  Annandale, VA

 

  Chapter
10   MEDIA

 

10.1   WHO Book 2013

< 

10. 2  Molecular Kinetics. Video. Presentation at the
NIH Symposium on Single Cell Analysis NIH, Bethesda MD, 2013

 

10. 3  Single Cell Analysis Enzyme Kinetics. Short
version, Video, 2013

 

10. 4
Telemedicine in Cervical Cancer Screening. Video, Johns Hopkins University,
Rockville, MD, 2012

 

10.5  Cervical Cancer Screening in India. PPP
presentation with sound, 2013

 

10.6   Molecular Kinetics and Drug Testing. Slide
Show, NIH, Bethesda, MD, 2012

 

10.7  Media Content

 

 

This book (an updated and extended
edition) is about mobilizing women and health care policy makers and providers
to unite their efforts in a single strategy for fighting cervical cancer
worldwide. The objective of this strategy would be to reverse cervical cancer
prevalence and mortality rates among all 2.4 billion women at risk and to
achieve this goal within 10-15 years of implementation. Cervical Cancer
Screening (Pap test, VIA, VILI, or HPV) failed to stop cervical cancer
worldwide simply because many countries could not afford developing
infrastructure necessary to carry on the global strategy, and because the
outreach could not accomplish the targeted 51% of the population at risk. In
2015, there is still 600,000 women getting cervical cancer annually and 300,000
of them die. Every minute one woman gets cervical cancer and every 2 minutes
one woman dies from this preventable disease.

In 21st Century the
Information Technology (IT) Revolution has made substantial impact on medicine
enabling remote points-of care, scattered around the world, to be e-connected
with experts in distant medical centers and to obtain quality diagnosis and
proper guidelines for curative therapy of early stages of cervical cancer.  Low frequency of costly interventions needed
makes IT-based screening financially and socially beneficial for mass
screening.  

This new Mobile Health technology
with the Global Strategy for Fighting Cervical Cancer is subject to elaboration
in our book as the new hope when old efforts have failed to stop the world
“epidemics” of this grave but preventable disease. The language is adapted for
easy reading and understanding by professionals and lay-persons                    

This book is intended for women at
risk for cervical cancer, their health care providers, health insurance
companies, government responsible for making health policy and healthcare
industry because all of them have special role in the new Global Strategy
elaborated in details in this book. 

Actuality of the subject

One-stop comprehensive cervical cancer resource

Novelties in the field heralding future policy and standards

Personal position of authors on controversial issues

Balancing needs for developed and developing countries